Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/131238
Название: Triazavirin—A Novel Effective Antiviral Drug
Авторы: Chupakhin, O. N.
Rusinov, V. L.
Varaksin, M. V.
Ulomskiy, E. N.
Savateev, K. V.
Butorin, I. I.
Du, W.
Sun, Z.
Charushin, V. N.
Дата публикации: 2022
Издатель: MDPI
Библиографическое описание: Chupakhin, ON, Rusinov, VL, Varaksin, MV, Ulomskiy, EN, Savateev, KV, Butorin, II, Du, W, Sun, Z & Charushin, VN 2022, 'Triazavirin—A Novel Effective Antiviral Drug', International Journal of Molecular Sciences, Том. 23, № 23, 14537. https://doi.org/10.3390/ijms232314537
Chupakhin, O. N., Rusinov, V. L., Varaksin, M. V., Ulomskiy, E. N., Savateev, K. V., Butorin, I. I., Du, W., Sun, Z., & Charushin, V. N. (2022). Triazavirin—A Novel Effective Antiviral Drug. International Journal of Molecular Sciences, 23(23), [14537]. https://doi.org/10.3390/ijms232314537
Аннотация: This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug. © 2022 by the authors.
Ключевые слова: ANTIVIRAL THERAPY
COVID-19
RIAMILOVIR
SARS-COV-2
TRIAZAVIRIN
ANIMALS
ANTIVIRAL AGENTS
AZOLES
COVID-19
ENCEPHALITIS, TICK-BORNE
HUMANS
INFLUENZA, HUMAN
OSELTAMIVIR
OXYGEN RADICAL
RIAMILOVIR
ANTIVIRUS AGENT
PYRROLE DERIVATIVE
AIRWAY EPITHELIUM CELL
ALKYLATION
ANTIMICROBIAL ACTIVITY
ANTINEOPLASTIC ACTIVITY
ANTIVIRAL ACTIVITY
ANTIVIRAL THERAPY
BILIRUBIN BLOOD LEVEL
BIOLOGICAL FUNCTIONS
CHEMICAL REACTION
CLINICAL PRACTICE
COMPARATIVE STUDY
CORONAVIRUS DISEASE 2019
DISSOCIATION CONSTANT
DRUG BIOAVAILABILITY
DRUG EFFICACY
ELIMINATION HALF-LIFE
HUMAN
HYDROGEN BOND
INFLUENZA A VIRUS (H7N3)
INFLUENZA A VIRUS (H9N2)
INFLUENZA VIRUS
KIDNEY FUNCTION
LUNG PARENCHYMA
MOLECULAR MODEL
NITROSYLATION
NONHUMAN
OXIDATIVE STRESS
OXYGEN BREATHING
POLYMERASE CHAIN REACTION
REACTION TEMPERATURE
REGIOSELECTIVITY
REVIEW
RIFT VALLEY FEVER
RING OPENING
ROOM TEMPERATURE
RUSSIAN FEDERATION
STATIC ELECTRICITY
STEREOSPECIFICITY
SUBSTITUTION REACTION
TAUTOMER
TICK BORNE ENCEPHALITIS
TICK BORNE ENCEPHALITIS VIRUS
VIRUS REPLICATION
WEST NILE FEVER
X RAY CRYSTALLOGRAPHY
ANIMAL
INFLUENZA
TICK BORNE ENCEPHALITIS
URI: http://elar.urfu.ru/handle/10995/131238
Условия доступа: info:eu-repo/semantics/openAccess
cc-by
Текст лицензии: https://creativecommons.org/licenses/by/4.0/
Идентификатор SCOPUS: 85143736704
Идентификатор WOS: 000897437000001
Идентификатор PURE: 32888400
a2205dfe-145a-485a-b788-c0f8bd695a31
ISSN: 1661-6596
DOI: 10.3390/ijms232314537
Сведения о поддержке: National Natural Science Foundation of China, NSFC, (20-53-55003, 82161148007)
Russian Foundation for Basic Research, РФФИ
Ministry of Education and Science of the Russian Federation, Minobrnauka, (FEUZ-2022-0001)
This work was supported by the Ministry of Science and Higher Education of the Russian Federation (Project No FEUZ-2022-0001), RFBR and NSFC (RFBR project No 20-53-55003, NSFC project number No 82161148007).
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85143736704.pdf8,35 MBAdobe PDFПросмотреть/Открыть


Лицензия на ресурс: Лицензия Creative Commons Creative Commons